STAR_PAC: A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab¬Paclitaxel for pancreatic cancer

Published on Jun 1, 2016in Pancreatology3.629
· DOI :10.1016/J.PAN.2016.04.019
Hemant M. Kocher41
Estimated H-index: 41
(QMUL: Queen Mary University of London),
David Propper27
Estimated H-index: 27
(QMUL: Queen Mary University of London)
+ 13 AuthorsPeter Sasieni77
Estimated H-index: 77
(QMUL: Queen Mary University of London)
📖 Papers frequently viewed together
67 Citations
Cited By4
#1Yang Wu (LMU: Ludwig Maximilian University of Munich)H-Index: 5
#2Chun Zhang (LMU: Ludwig Maximilian University of Munich)
Last. Jan G. D'Haese (LMU: Ludwig Maximilian University of Munich)H-Index: 16
view all 6 authors...
Pancreatic ductal adenocarcinoma (PDAC) is a gastrointestinal malignancy with a dismal clinical outcome. Accumulating evidence suggests that activated pancreatic stellate cells (PSCs), the major producers of extracellular matrix (ECM), drive the severe stromal/desmoplastic reaction in PDAC. Furthermore, the crosstalk among PSCs, pancreatic cancer cells (PCCs) as well as other stroma cells can establish a growth-supportive tumor microenvironment (TME) of PDAC, thereby enhancing tumor growth, meta...
6 CitationsSource
#1Jonas Schnittert (UT: University of Twente)H-Index: 8
#2Ruchi Bansal (UT: University of Twente)H-Index: 20
Last. Jai Prakash (UT: University of Twente)H-Index: 55
view all 3 authors...
Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis with a 5-year survival rate of 8%. PSCs constitute more than 50% of the tumor stroma in PDAC, where they induce extensive desmoplasia by secreting abundant extracellular matrix (ECM) proteins. In addition, they establish dynamic crosstalk with cancer cells and other stromal cells, which collectively supports tumor pr...
45 CitationsSource
#1Stefano Coppola (LEI: Leiden University)H-Index: 7
#2Ilaria Carnevale (VUmc: VU University Medical Center)H-Index: 11
Last. Elisa Giovannetti (VUmc: VU University Medical Center)H-Index: 58
view all 7 authors...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly chemoresistant malignancy. This chemoresistant phenotype has been historically associated with genetic factors. Major biomedical research efforts were concentrated that resulted in the identification of subtypes characterized by specific genetic lesions and gene expression signatures that suggest important biological differences. However, to date, these distinct differences could not be exploited for therapeutic interventions. Apart fr...
26 CitationsSource